But the future of these new interventions cannot hinge on excitement and speculation alone. Sustainable success requires a fundamental shift towards intentional development.<\/p>\n
That shift is now being applied to the precision medicine industry, where the science driving these interventions is not met equally by the ability to commercialize them and the ability to pay for them. High costs and manufacturing complexity collide with hard questions about commercial viability, regulation and cost coverage. Investor exuberance fades. High-profile programs shut down.\u00a0<\/p>\n
Yet, the global market is projected to grow<\/a> from $22 billion worldwide in 2024 to over $120 billion in 2034, almost 19% per year. While the US remains the largest market, Asia is the fastest-growing.\u00a0<\/p>\n If the United States does not invest in cementing life sciences leadership, we will lose the life sciences race.<\/p>\n Why here, why now?<\/p>\n Few other regions in the country have the breadth and depth of assets in precision medicine that we have in Greater Philadelphia and the ability to address these national challenges. We\u2019ve done this before.\u00a0<\/p>\n The early days of antibody therapeutics, led by Centocor,<\/a> also carried prohibitively high costs and limited targets, yet became broadly accessible through coordinated infrastructure, process innovation and technology advancement, and now represents an over $200 billion market.\u00a0<\/p>\n Now we have the same opportunity, kick-started by Philadelphia-based Spark Therapeutics\u2019 (now Roche) Luxterna, the FDA\u2019s first-ever approval of gene therapy for inherited disease<\/a>. This isn\u2019t just legacy \u2014 it\u2019s momentum. The regional infrastructure is catching up to the science to keep it moving forward. We can invent it here, validate it here, make it here, test it here, house it here, people it here and keep it here.\u00a0<\/p>\n A quick scan of the region\u2019s \u201cwhere it happens\u201d buildout shows how fast Greater Philadelphia is expanding its life-sciences footprint. Led by Wexford<\/a> and Brandywine<\/a>, it collectively represents over 1.7 million square feet and nearly $2 billion in private investment in new labs, offices and manufacturing space delivered in the last three years.\u00a0<\/p>\n Hubs like the Bellwether District, Delaware Innovation Space<\/a> and the Pennovation Center<\/a> are already delivering new capacity, while projects like Breakthrough<\/a>, the Coriell Innovation Center in Camden<\/a> and other sites remain under construction.\u00a0<\/p>\n We may never be Boston<\/a> \u2014 we don\u2019t need to be \u2014 but that shouldn\u2019t diminish the assets and accomplishments we do have, and investment in the region is growing:\u00a0<\/p>\n Merck began construction on<\/a> a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, with expectations of more than 500 full-time roles, lab operations by 2028 and investigational production by 2030.<\/p>\n Thermo Fisher opened its East Coast flagship<\/a> Advanced Therapies Collaboration Center in Philadelphia, inside a newly expanded 53,000-square-foot BioLabs for Advanced Therapeutics space, designed to give startups direct access to expert scientists and advanced process development.<\/p>\n
![\"A](\"https:\/\/www.newsbeep.com\/us-pa\/wp-content\/uploads\/2025\/12\/Table-3.png\")
New therapeutic indications and platform technologies being developed by regional companies and research institutions (Courtesy Ben Franklin Technology Partners)<\/p>\n